Recent posts

The Evolving Regulations Guiding Nitrosamines

By October 19, 2020

In July 2018, the European Medicines Agency (EMA) reported the recall of a number of products containing the active pharmaceutical ingredient (API) valsartan due to contamination with a known carcinogen, dimethyl nitrosamine, also referred to… Read more >

Categories: Pharmaceutical
Tags:

Mutagenic Impurity Risk Assessment Throughout the Development and Manufacturing Process

By September 15, 2020

Since the early 2000s and the advent of the first guidance relating to mutagenic impurities developed by the European Medicines Agency (EMA), it has been necessary to assess the risk posed by mutagenic impurities.  Although… Read more >

Categories: Pharmaceutical
Tags: , , ,

Bringing the Future Into Focus with Waters’ Virtual Events

By August 25, 2020

In the midst of the COVID-19 pandemic the power of technology has emerged center stage, keeping the industry connected at a time when many ordinary avenues of communication have been cut off over safety concerns.… Read more >

Categories: Automation, Chemical, Columns, COVID-19, Food & Environmental, Leadership, Pharmaceutical, Technologies

Waters GlycoWorks RapiFluor-MS N-Glycan Kit Improves Reproducibility and Speed of N-Glycan Analysis Through Innovation and Automation

By July 22, 2020

Glycosylation is an important post-translational modification that can impact the safety and efficacy of protein therapeutics and is therefore one of the most analyzed product attributes during development and quality control. In released N-glycan analysis, glycans are cleaved from proteins via enzymatic digestion and are chemically derivatized for relative quantification by liquid chromatography coupled… Read more >

Categories: Automation, Pharmaceutical
Tags: ,

The Impact of Complex Global Supply on the Nitrosamine Crisis

By July 9, 2020

When a crisis occurs, hindsight is a great teacher. Any company developing or manufacturing products that impact human health can learn from the recent nitrosamine impurity contamination of angiotensin II receptor blockers (ARBs) by reviewing… Read more >

Categories: Pharmaceutical
Tags: , , , , ,

Change Up Your Routine (Analysis)

By June 23, 2020

Enhancing performance, mitigating risk, and improving efficiency Today, Waters introduced the Arc HPLC, a modern liquid chromatography system that replicates established test methods while delivering improved performance. HPLC has been a cornerstone of routine analytical… Read more >

Categories: Data Integrity, Pharmaceutical, Technologies
Tags: , , , ,

Reveal Molecular Secrets – and Set Them to Work!

By June 23, 2020

From fundamental research to routine analysis, Waters’ latest innovations in mass spectrometry enable our customers to gain – and apply – insights across the scientific spectrum. Beginning with fundamental research where the focus is on… Read more >

Categories: Pharmaceutical, Technologies
Tags: , ,

Navigating the Uncertainties of the Nitrosamine Impurity Crisis

By March 26, 2020

The nitrosamine impurity crisis continues to be on the mind of every stakeholder involved in the development and manufacturing of affected drug products. In our interactions with key opinion leaders and those in the lab having to develop and validate nitrosamine testing methods, we’ve come across a few common questions that we want to address here

Categories: Pharmaceutical
Tags: ,

Nitrosamine Impurities: The Need to Verify

By December 17, 2019

The recent nitrosamine impurity crisis has brought into question the quality of many APIs (Active Pharmaceutical Ingredients) produced and sourced for a number of popular drugs, resulting in product recalls, lost profits, and regulatory actions.… Read more >

Categories: Pharmaceutical
Tags: ,

Webinar Highlights – Improving Analytical Method Performance Through Quality Risk Management and a Design of Experiments Approach

By November 7, 2019

In our most recent Method Lifecycle Management webinar held Improving Analytical Method Performance Through Quality Risk Management and a Design of Experiments Approach, Joseph A. Turpin, Director of Chromatography Products and Services at S-Matrix Corporation and Tran Pham, Business Development Manager at Waters Corporation, presented an overview of Quality by Design approaches to analytical method development (AQbD), the regulatory views on this approach, examples of design of experiments in AQbD, and case studies demonstrating software assisted AQbD method development.

Categories: Pharmaceutical
Tags: , , , , , , ,